Key Drivers
- Liquidity cushion
- Heavy leverage
- Negative cash flow
AIAI Summary
PRGO is now a balance-sheet repair story, not a simple cheap consumer-health play: the stock can re-rate only if management converts asset sales and Specialty Care momentum into sustained free cash flow and faster deleveraging, because persistent losses, erratic cash burn, and CEO turnover keep the turnaround highly execution-dependent.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity cushion
- •Heavy leverage
- •Negative cash flow
Pergo shows weak profitability and cash-flow pressure despite adequate near-term liquidity, as persistent losses, heavy leverage, and negative quarterly EBITDA outweigh its low valuation multiples.
Price Behavior
Key Price Behavior Insights:
- •Rebound Support
- •Overhead Resistance
- •Mixed Momentum
PRGO has turned constructive after rebounding from $9.49 to $11.02, but it remains range-bound with support near $10.00-$10.70 and resistance at $11.20-$11.61 that must clear for confirmation.
Sharp drop from the 2026-06-08 peak to the 2026-06-23 low showed a clear mid-period momentum break
Sentiment & News
Key News Insights:
- •Dividend risk
- •CEO exit
- •Board refresh
Perrigo is facing ongoing stock weakness, leverage and dividend-sustainability concerns, and a major governance reset after the CEO's exit and board refresh. ക
The combination of financial strain and leadership turnover likely keeps pressure on PRGO's valuation and investor confidence in the near term
Similar Companies in Healthcare
Other companies in the same sector with AI ratings